Pediatric-Friendly Formulations: Critical to Maximizing Benefit of Novel Therapeutics Such as Selumetinib for Children With Neurofibromatosis and Other Neoplasms

Journal of Clinical Oncology 2026

View at publisher
Authors: Melanie Brooke Bernhardt, Brenda J. Weigel
DOI: 10.1200/jco-25-02765
Cited by: 0
References: 17

Fields of Study & Subjects

Pharmaceutical studies and practices Neurofibromatosis and Schwannoma Cases Neuroblastoma Research and Treatments

Publication details

Journal / source
Journal of Clinical Oncology
Volume
44
Issue
10
Pages
832–834
Publication date
27 January 2026
Language
EN